Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease
Status:
Recruiting
Trial end date:
2022-08-15
Target enrollment:
Participant gender:
Summary
The investigators will see if the drug teriflunomide (which is in use in other immune
disorder (multiple sclerosis)) can inhibit the immune activation in celiac disease patients
during a 3 day gluten challenge. This will be measured in a blood sample.